Biofrontera Inc. BFRI
0.70 USD -0.23 (-24.39%)
At closeNov 13, 2026, 6:58 PM EST
0.73 +0.03 +4.27%
After hours · Nov 13, 6:58 PM ET
0.6888 Day range 0.96
0.555 52-week range 1.66
- YTD
- +22.82%
- 1 year
- -21.34%
News
seekingalpha.com Biofrontera Inc. (BFRI) Q3 2026 Earnings Call Transcript Biofrontera Inc. (BFRI) Q3 2026 Earnings Call Transcript
benzinga.com Biofrontera Q3 EPS $(0.42) Misses $(0.11) Estimate, Sales $9.100M Beat $8.500M Estimate Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.11) by 281.82 percent. This is a 32.26 percent increase over losses of…
globenewswire.com Biofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth WOBURN, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of…
globenewswire.com Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026 WOBURN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S.-based biopharmaceutical company engaging in the development, manufacturing,…
benzinga.com Biofrontera Refiles Supplemental New Drug Application For Ameluz Topical Gel To FDA To Treat Actinic Keratoses Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today
globenewswire.com Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body Submission seeks to extend the Ameluz ® label beyond the face and scalp to treatment fields of up to approximately 240 cm² on the rest of the body, with an adjusted illumination protocol
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Flyte Aviation, Inc. Common Stock (AMEX:VJET) stock moved upwards by 34.0% to $2.17 during Monday's after-market session. Option Care Health (NASDAQ:OPCH) shares rose 20.92% to $28.26. The…
defenseworld.net Biofrontera (NASDAQ:BFRI) & Astrazeneca (NYSE:AZN) Critical Contrast Astrazeneca (NYSE: AZN - Get Free Report) and Biofrontera (NASDAQ: BFRI - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies…
benzinga.com Transcript: Biofrontera Q2 2026 Earnings Conference Call On Thursday, Biofrontera (NASDAQ:BFRI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…
benzinga.com Biofrontera Receives FDA Supplemental New Drug Application Approval For Its Ameluz Topical Gel, 10%, In Combination With Photodynamic Therapy Using The BF-RhodoLED Lamp Series For The Treatment Of Superficial Basal Cell Carcinoma In Adults With this approval, Ameluz becomes the first and only PDT drug approved by the FDA for the treatment of a skin cancer, and the only topical PDT in the United States indicated to treat both a…
globenewswire.com Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million. Biodexa Pharmaceuticals (NASDAQ:BDRX)…
seekingalpha.com Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript
zacks.com Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.57 per share a year ago.- benzinga.com Biofrontera Q2 EPS $(0.05) Misses $(0.04) Estimate, Sales $12.003M Beat $10.500M Estimate Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 91.23 percent increase over losses of $(0.57)…
globenewswire.com Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of…
globenewswire.com Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026 WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid…
seekingalpha.com Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript
globenewswire.com Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 WOBURN, Mass. , May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of…
benzinga.com This Hanover Insurance Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday Wall Street analysts changed ratings on top names. Check our analyst ratings page for full updates. THG, BFRI covered.
benzinga.com This Stubhub Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. See what other analysts think of these stocks.
benzinga.com Benchmark Downgrades Biofrontera to Speculative Buy, Maintains Price Target to $3 Benchmark analyst Bruce D. Jackson downgrades Biofrontera (NASDAQ:BFRI) from Buy to Speculative Buy and maintains the price target from $3 to $3.- benzinga.com Transcript: Biofrontera Q1 2026 Earnings Conference Call
zacks.com Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.47 per share a year ago.- benzinga.com Biofrontera Q1 EPS $(0.41) Misses $(0.12) Estimate, Sales $10.084M Miss $10.250M Estimate Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.12) by 272.73 percent. This is a 12.77 percent increase over losses of…
globenewswire.com Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy…
benzinga.com Earnings Scheduled For May 14, 2026 
globenewswire.com Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis The second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosis (AK) Awareness Day This social media–driven initiative invites people to wear a hat, share a…
globenewswire.com Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026 WOBURN, Mass. , May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of…
defenseworld.net Biofrontera Q4 Earnings Call Highlights Biofrontera (NASDAQ: BFRI) reported record revenue for both the fourth quarter and full year 2025, driven by higher Ameluz photodynamic therapy (PDT) demand and a major change to its U.S. rights and…- benzinga.com Biofrontera Q4 EPS $0.48 Beats $0.20 Estimate, Sales $17.100M Beat $16.146M Estimate Biofrontera (NASDAQ:BFRI) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.20 by 146.15 percent. This is a 352.63 percent increase over losses of $(0.19)…
seekingalpha.com Biofrontera Inc. (BFRI) Q4 2025 Earnings Call Transcript Biofrontera Inc. (BFRI) Q4 2025 Earnings Call Transcript- benzinga.com Earnings Scheduled For March 19, 2026
benzinga.com Biofrontera Announces US Patent Trial And Appeal Board Final Written Decision Finding All Challenged Claims Of Sun Pharma's '028 Patent To Be Unpatentable Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy ("PDT"), today announced that on February 23, 2026, the U.S.…
benzinga.com Biofrontera's Supplemental New Drug Application For Ameluz Accepted By FDA Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (PDT), today announced that…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Biofrontera Announces Results From 172 Participants In Its Phase 3 Cliical Study Of Ameluz Photodynamic Therapy To Treat Actinic Keratoses Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Biofrontera Expects Q4 Revenue Between $17M - $17.5M, FY25 Revenue Between $41.5M - $42M Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for…
benzinga.com Biofrontera Locks Databases For Treatment Phase Of Phase 3 Clinical Trial Of Ameluz PDT, Phase 2 Clinical Trial To Treat Moderate To Severe Acne Vulgaris Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Why Baidu Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Biofrontera Transfers Of Ameluz, RhodoLED New Drug Applications, Investigational New Drug Applications; Completes Requirements For Transfer Of All U.S., Some Global Intellectual Property Associated With Ameluz And RhodoLED Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced the completion of the transfer of the FDA…
- benzinga.com Biofrontera Completes Final Patient Visit In Phase 1 Pharmacokinetic Study Of Ameluz Gel, 10%, For Treatment Of Mild To Moderate Actinic Keratoses On Neck, Trunk And Extremities Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz® over treatment area of 240 cm2Completion of this study marks a key milestone…
- benzinga.com Biofrontera Files sNDA For Ameluz-PDT To Treat sBCC After Phase 3 Trial Achieves 65.5% Complete Clearance Of Main Target Lesions; Primary And Key Secondary Endpoints Met With High Statistical Significance With Favorable One-Year Recurrence and Aesthetic Outcomes sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to…
benzinga.com Biofrontera Q3 EPS $(0.62) Misses $(0.58) Estimate, Sales $6.988M Miss $7.000M Estimate Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.58) by 6.9 percent. This is a 36.73 percent increase over losses of $(0.98)…